Correlation Between Monopar Therapeutics and Satsuma Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Satsuma Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Satsuma Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Monopar Therapeutics and Satsuma Pharmaceuticals, you can compare the effects of market volatilities on Monopar Therapeutics and Satsuma Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Satsuma Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Satsuma Pharmaceuticals.
Diversification Opportunities for Monopar Therapeutics and Satsuma Pharmaceuticals
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Monopar and Satsuma is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Satsuma Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Satsuma Pharmaceuticals and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Satsuma Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Satsuma Pharmaceuticals has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Satsuma Pharmaceuticals go up and down completely randomly.
Pair Corralation between Monopar Therapeutics and Satsuma Pharmaceuticals
Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 3.65 times more return on investment than Satsuma Pharmaceuticals. However, Monopar Therapeutics is 3.65 times more volatile than Satsuma Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. Satsuma Pharmaceuticals is currently generating about 0.07 per unit of risk. If you would invest 1,830 in Monopar Therapeutics on November 2, 2024 and sell it today you would earn a total of 2,420 from holding Monopar Therapeutics or generate 132.24% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 16.4% |
| Values | Daily Returns |
Monopar Therapeutics vs. Satsuma Pharmaceuticals
Performance |
| Timeline |
| Monopar Therapeutics |
| Satsuma Pharmaceuticals |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Monopar Therapeutics and Satsuma Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Monopar Therapeutics and Satsuma Pharmaceuticals
The main advantage of trading using opposite Monopar Therapeutics and Satsuma Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Satsuma Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Satsuma Pharmaceuticals will offset losses from the drop in Satsuma Pharmaceuticals' long position.| Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
| Satsuma Pharmaceuticals vs. Erasca Inc | Satsuma Pharmaceuticals vs. Forte Biosciences | Satsuma Pharmaceuticals vs. SAB Biotherapeutics | Satsuma Pharmaceuticals vs. Senti Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |